Can regional hyperthermia plus chemotherapy improve survival for extremity soft tissue sarcoma?
Regional hyperthermia (RHT) is a treatment that heats the tumor area to make chemotherapy work better. For extremity soft tissue sarcoma (ESTS), a post-hoc analysis of the EORTC 62961-ESHO 95 trial found that adding RHT to neoadjuvant chemotherapy (NAC) improved overall survival compared to NAC alone, with a 15.6% absolute improvement in 5-year survival. However, this was a subgroup analysis, and results did not reach statistical significance (p=0.081). Other studies in advanced soft tissue sarcoma have shown mixed results, so the evidence is promising but not definitive.
What the research says
A post-hoc analysis of the EORTC 62961-ESHO 95 trial specifically looked at patients with extremity soft tissue sarcoma (ESTS) 2. Among 135 patients, those who received NAC plus RHT had better overall survival than those who received NAC alone, with a hazard ratio of 0.67 (95% CI 0.39-1.17, p=0.081) 2. The absolute 5-year survival difference was 15.6% (95% CI 0.0%-31.4%) 2. While not statistically significant, this suggests a potential benefit.
The original EORTC trial (published in JAMA Oncology 2018) included all localized high-risk soft tissue sarcomas and found that adding RHT to neoadjuvant chemotherapy improved local progression-free survival and overall survival 7. That trial used doxorubicin, ifosfamide, and etoposide 7.
However, a more recent randomized trial (HyperTET) tested trabectedin plus RHT versus trabectedin alone in advanced soft tissue sarcoma and found no significant difference in progression-free survival (median 3.0 vs 3.5 months, HR 0.86, p=0.459) 5. This suggests the benefit of RHT may depend on the chemotherapy regimen or disease stage.
Another retrospective study in leiomyosarcoma (a type of soft tissue sarcoma) found that doxorubicin plus dacarbazine with RHT improved progression-free survival compared to doxorubicin plus ifosfamide with RHT (HR 0.32, p=0.0081) 6. This highlights that the choice of chemotherapy matters.
Other sources discuss prognostic markers (like NLR) or second-line treatments but do not directly address the question of RHT plus chemotherapy for survival 134.
What to ask your doctor
- Is regional hyperthermia available at a center near me, and am I a candidate for this treatment?
- What chemotherapy regimen would be used with hyperthermia, and what does the evidence show for my specific sarcoma subtype?
- What are the potential side effects of adding hyperthermia to chemotherapy?
- How does the 15.6% absolute survival benefit seen in the extremity sarcoma subgroup compare to other treatment options?
- Should I consider clinical trials testing hyperthermia combinations?
This question is drawn from common patient questions about Oncology and answered using cited medical research. We do not provide individualized advice.